Neos Therapeutics

Neos Therapeutics develops, manufactures, and commercializes branded products using our proprietary, extended-release drug delivery technology platform. We have used this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. We are also using this technology to develop two additional product candidates: Oral disintegrating tablets (ODT) Oral suspension dosage forms.
Company Growth (employees)
Grand Prairie, US
Size (employees)
81 (est)
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US

Key People at Neos Therapeutics

Vipin Garg

Vipin Garg

Richard Eisenstadt

Richard Eisenstadt

Russ McMahen

Russ McMahen

Executive Vice President of Operations and Vice President of Scientific Affairs
Ellen Hoffing

Ellen Hoffing

Co-President & Chief Operating Officer
Dorothy Engelking

Dorothy Engelking

VP of Regulatory Affairs
Margaret Cabano

Margaret Cabano

VP of Operations

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie, Blue Bell
Grand Prairie, US
Blue Bell, US

Neos Therapeutics Metrics

Neos Therapeutics Summary

Market capitalization

$107.2 m

Closing share price

Neos Therapeutics's current market capitalization is $107.2 m.

Neos Therapeutics Financials

Neos Therapeutics's revenue is $3.8 m in FY, 2015
FY, 2015


$3.8 m

Net Income

($30.8 m)

Neos Therapeutics Market Value History

Neos Therapeutics News

Neos Therapeutics Company Life

You may also be interested in